Lexicon Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Lexicon Pharmaceuticals
LXRX Stock  USD 0.80  0.02  2.44%   
Lexicon Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Lexicon Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lexicon Pharmaceuticals financial statements helps investors assess Lexicon Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lexicon Pharmaceuticals' valuation are summarized below:
Gross Profit
-52.7 M
Market Capitalization
291 M
Enterprise Value Revenue
25.5036
Revenue
5.2 M
Earnings Share
(0.74)
We have found one hundred twenty available fundamental ratios for Lexicon Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Lexicon Pharmaceuticals last-minute market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 403 M in 2024, whereas Enterprise Value is likely to drop slightly above 363.8 M in 2024.

Lexicon Pharmaceuticals Total Revenue

1.14 Million

Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 526.3 K, Interest Expense of 13.8 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 209, Dividend Yield of 0.0 or PTB Ratio of 5.52. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Lexicon Pharmaceuticals Correlation against competitors.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Lexicon Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets326.8 M229.4 M328.7 M
Pretty Stable
Short and Long Term Debt Total76.2 M106.1 M94.1 M
Pretty Stable
Total Current Liabilities48.4 M31.5 M53.6 M
Very volatile
Property Plant And Equipment Net7.1 M7.5 M16.5 M
Slightly volatile
Accounts Payable13.3 M14.4 M16.7 M
Very volatile
Cash21.3 M22.5 M175.4 M
Slightly volatile
Non Current Assets Total104.9 M52.9 M92.8 M
Slightly volatile
Non Currrent Assets Other786.6 K828 K1.8 M
Pretty Stable
Cash And Short Term Investments206.8 M170 M223.1 M
Pretty Stable
Net Receivables959.5 K1 M5.7 M
Very volatile
Common Stock Shares Outstanding232.2 M221.1 M112.2 M
Slightly volatile
Short Term Investments137 M147.6 M146.5 M
Very volatile
Non Current Liabilities Total100.6 M104.8 M123.7 M
Very volatile
Other Current Assets7 M5.1 M6.3 M
Very volatile
Total Liabilities149 M136.3 M177.3 M
Very volatile
Property Plant And Equipment Gross11.4 M12 M18.1 M
Slightly volatile
Total Current Assets221.8 M176.5 M235.9 M
Pretty Stable
Short Term Debt1.1 M1.2 M7.9 M
Slightly volatile
Long Term Debt77.2 M99.5 M91.7 M
Slightly volatile
Common Stock Total Equity212.7 K217.3 K247.9 K
Slightly volatile
Property Plant Equipment1.8 M1.9 M16.1 M
Slightly volatile
Other Liabilities43.1 M26.8 M45.3 M
Pretty Stable
Good Will40.9 M51.2 M43.5 M
Slightly volatile
Intangible Assets41.5 M22.7 M38.1 M
Slightly volatile
Long Term Debt Total282.8 M269.3 M155.3 M
Slightly volatile
Capital Surpluse1.5 B2 B1.4 B
Slightly volatile
Deferred Long Term Liabilities52.6 M34.1 M41.4 M
Very volatile
Non Current Liabilities Other4.6 M4.9 M15.5 M
Slightly volatile
Short and Long Term Debt8.7 M10.5 M13.3 M
Slightly volatile
Net Invested Capital173.6 M192.6 M251.8 M
Slightly volatile
Net Working Capital119.7 M145 M170.1 M
Slightly volatile
Capital Stock172 K245 K130.5 K
Slightly volatile
Capital Lease Obligations3.9 M6.6 M2.1 M
Slightly volatile

Lexicon Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization526.3 K554 K4.2 M
Very volatile
Total Revenue1.1 M1.2 M49.9 M
Very volatile
Other Operating Expenses145.3 M173 M136.1 M
Slightly volatile
Research Development97.4 M58.9 M93.9 M
Very volatile
Total Operating Expenses145.1 M172.9 M135.6 M
Slightly volatile
Selling General Administrative102.6 M97.7 M41.6 M
Slightly volatile
Non Operating Income Net Other1.9 M1.8 M1.6 M
Slightly volatile
Interest Income6.5 M6.2 M4.6 M
Slightly volatile
Reconciled Depreciation484.5 K510 K2.6 M
Slightly volatile
Extraordinary Items3.2 M3.6 M3.9 M
Slightly volatile

Lexicon Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow66.6 M46.3 M78.2 M
Very volatile
Depreciation526.3 K554 K2.3 M
Slightly volatile
Capital Expenditures446.5 K470 K845.6 K
Slightly volatile
End Period Cash Flow21.3 M22.5 M73.4 M
Pretty Stable
Stock Based Compensation9.7 M14.3 M9.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio209281435
Slightly volatile
Days Sales Outstanding322306121
Very volatile
Stock Based Compensation To Revenue6.511.910310.0405
Slightly volatile
Capex To Depreciation0.660.84840.8905
Pretty Stable
EV To Sales194350403
Slightly volatile
Inventory Turnover0.240.266.606
Slightly volatile
Days Of Inventory On Hand1.5 K1.5 K548
Slightly volatile
Sales General And Administrative To Revenue327311137
Slightly volatile
Average Inventory0.550.57883.3 K
Very volatile
Research And Ddevelopement To Revenue26.8248.909555.0774
Slightly volatile
Capex To Revenue0.60.39041.16
Slightly volatile
Cash Per Share0.730.76893.6784
Slightly volatile
Intangibles To Total Assets0.150.19410.2245
Very volatile
Current Ratio7.025.59655.692
Pretty Stable
Receivables Turnover1.131.192120.7067
Very volatile
Graham Number2.622.754710.5231
Slightly volatile
Capex Per Share0.0020.00210.0842
Slightly volatile
Average Receivables2.7 M3.3 M3.6 M
Pretty Stable
Revenue Per Share0.00520.00540.5667
Pretty Stable
Interest Debt Per Share0.480.50921.1642
Slightly volatile
Debt To Assets0.460.43370.323
Pretty Stable
Operating Cycle2 K1.9 K475
Slightly volatile
Quick Ratio7.015.58445.6805
Pretty Stable
Net Income Per E B T0.540.910.9676
Slightly volatile
Cash Ratio0.680.71214.046
Slightly volatile
Days Of Inventory Outstanding1.5 K1.5 K548
Slightly volatile
Days Of Sales Outstanding322306121
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.431.00291.0617
Very volatile
Fixed Asset Turnover0.150.16039.7462
Pretty Stable
Debt Ratio0.460.43370.323
Pretty Stable
Price Sales Ratio209281435
Slightly volatile
Asset Turnover0.0050.00520.132
Very volatile

Lexicon Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap403 M396.7 M651.5 M
Slightly volatile
Enterprise Value363.8 M708.4 M702.4 M
Pretty Stable

Lexicon Fundamental Market Drivers

Cash And Short Term Investments170 M

Lexicon Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lexicon Pharmaceuticals Financial Statements

Lexicon Pharmaceuticals investors use historical fundamental indicators, such as Lexicon Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue32.4 M20 M
Total Revenue1.2 M1.1 M
Cost Of Revenue85 K80.8 K
Stock Based Compensation To Revenue 11.91  6.50 
Sales General And Administrative To Revenue 311.33  326.90 
Research And Ddevelopement To Revenue 48.91  26.82 
Capex To Revenue 0.39  0.60 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(142.65)(135.52)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY